Cancer Immunotherapy
STING activation in cancer immunotherapy
... signaling following binding to and activating cyclic GMP-AMP synthase (cGAS). Specifically, in the presence of cytosolic double-stranded DNA (dsDNA), the intracellular nucleic acid sensor cGAS uses cytosolic ATP and GTP ...
13
Cancer Immunotherapy and Flow Cytometry in Immunotherapy Monitoring
... for cancer treatment continues to be developed and various strategies have been carried out including ...discuss cancer immunotherapy using T cell and immune checkpoint blockade therapy, as well as ...
7
Advances in Engineering Cells for Cancer Immunotherapy
... integrates the respective merits of nanoparticles as drug depots and cells with natural directional migration potency as active carriage [143, 144]. Huang et al. reported nanoparticle-conjugated T cells for enhanced ...
17
Targetless T cells in cancer immunotherapy
... new cancer immunotherapy protocols aiming to activate T cell mediated anti-tumor ...of cancer immune therapy is based on the capacity of T cells to kill cancer cells that present tumor antigen ...
5
Cancer immunotherapy: are we there yet?
... Cancer immunotherapy has already entered the main- stream of oncology ...of cancer cells by a variety of means (Table ...cell-based immunotherapy is allogeneic stem cell transplant for the ...
6
Peptide-based materials for cancer immunotherapy
... kill cancer cells unless a longer MHC II peptide was added ...effective cancer immunotherapy vaccines than earlier ...peptide-based cancer vaccines, a clinical application program has been ...
19
VACCINES AND ANTIBODIES FOR CANCER IMMUNOTHERAPY A REVIEW
... destroy cancer cells by recognizing specific antigens on their ...for cancer immunotherapy and a number of such products have gained approval for clinical ...
17
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
... diverse cancer types by mining the TCGA data ...targeted cancer immunotherapy was discussed by Zihai Li (Medical Uni- versity of South ...multiple cancer types in- cluding bladder ...
15
RNA Nanotechnology-Mediated Cancer Immunotherapy
... system[189-191], which may be applied to manipulations of immune cells (TAMs, B cells, and T cells) and tumor cells (Figure 8B). In addition, compared to the viral vectors with high immunogenicity, various types of ...
19
New opportunities for nanoparticles in cancer immunotherapy
... of cancer immunotherapy could also be im- proved by combining this approach with other modalities such as chemotherapy [85, 86], radiation therapy [87], photodynamic therapy (PDT) [88, 89], and photothermal ...
10
Cancer immunotherapy with Mucin-1 and cytokines
... GM-CSF has been shown to produce anti-tumour responses in several tumour models (Armstrong et al., 1996, Dranoff et al., 1993, Saito et al., 1994) including in a murine breast cancer m[r] ...
356
Driving an improved CAR for cancer immunotherapy
... T cells that have been genetically engi- neered to express a chimeric antigen receptor (CAR) have emerged as one of the most promising therapeutic approaches for cancer (1). Along with immune checkpoint blockade ...
5
Primer on tumor immunology and cancer immunotherapy
... breast cancer, rituximab (anti-CD20) for the treatment of lymphoma, and the recently approved immunoconjugate T-DM1, which fuses trastuzumab to a highly potent che- motherapy, emtansine (DM1 [deacetyl maytansine]) ...
9
Cancer Immunotherapy
... kidney cancer, ovarian cancer, and other ...National Cancer Institute have been promising, but its use may be limited because doctors might not be able to get TILs from all ...
19
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting
... likely play a large role in the value of cancer immunother- apy. The panel considered that if a validated biomarker was available, it would be used to direct treatment selec- tion for particular patients, monitor ...
10
Sialic acid mimetics for cancer immunotherapy
... in cancer cells simultaneously and hold great promise for cancer ...in cancer, but should also boost further studies on the therapeutic window of opportunities to apply these inhibitors in ...
294
Particulate based vaccines for cancer immunotherapy
... The concept of synthetic long peptide (SLP) vaccines was introduced by Melief et al. The SLPs are overlapping synthetic peptides of 15–35 amino acids that 1) cover the entire sequence o[r] ...
287
Defining the critical hurdles in cancer immunotherapy
... in immunotherapy trials [20], however this should not prevent investigators from incorporating novel strategies to assess immune compe- tence of patients enrolling in ...
15
TCR-like antibodies in cancer immunotherapy
... cervical cancer, adult T cell leukemia (ATL), primary effusion lymphoma (PEL), Kaposi’s sarcoma (KS), and Merkel cell carcinoma ...develop cancer even with the infection of an oncovirus [60, 63, ...
13
Targeting adenosine for cancer immunotherapy
... Many of the factors that favor adenosine generation— tissue disruption, hypoxia, ectonucleotidase expression, and inflammation—are highly characteristic of the tumor microenvironment [5]. Significant work has thus been ...
9